Valeant Finalizes Sale of Skin Treatment Drugs to Nestle

Jul 10, 2014

Business Standard

Swiss food giant Nestle announced today that it has completed its acquisition of Valeant Pharmaceuticals' commercialization rights to several key injectable aesthetic dermatology products in the U.S. and Canada.

The $1.4 billion deal, which included corrective facial aesthetic treatments Restylane, Perlane, Emervel and Dysport, was announced on May 28 but needed approval from regulators to be complete.

The products are already manufactured by Nestle's Galderma medical unit, so the deal will transfer the North American distribution rights from Valeant to Nestle.

Read the Business Standard press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments